GRI:NSD-GRI Bio Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.495

Change

+0.01 (+2.91)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-14.75 (-3.14%)

USD 118.90B
REGN Regeneron Pharmaceuticals Inc

-24.90 (-3.61%)

USD 73.95B
ARGX argenx NV ADR

-10.43 (-1.61%)

USD 40.41B
ALNY Alnylam Pharmaceuticals Inc

-5.07 (-1.85%)

USD 34.99B
ONC BeiGene, Ltd.

+1.55 (+0.71%)

USD 25.62B
RPRX Royalty Pharma Plc

+0.53 (+1.67%)

USD 18.12B
SMMT Summit Therapeutics PLC

-1.42 (-6.93%)

USD 17.52B
UTHR United Therapeutics Corporatio..

+7.67 (+2.22%)

USD 15.68B
INCY Incyte Corporation

-1.97 (-2.88%)

USD 14.29B
INSM Insmed Inc

+1.77 (+2.27%)

USD 13.70B

ETFs Containing GRI

IUKP:SW iShares UK Property UCITS.. 3.33 % 0.00 %

-0.02 (-0.46%)

USD 0.59B
UKPH:XETRA 3.23 % 0.00 %

-0.02 (-0.46%)

N/A
IUKP:LSE iShares UK Property UCITS 0.00 % 0.00 %

-2.23 (-0.46%)

USD 0.59B
UKRE:LSE iShares MSCI Target UK Re.. 0.00 % 0.00 %

-1.45 (-0.46%)

USD 0.10B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -40.25% 9% A- 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.25% 9% A- 5% F
Trailing 12 Months  
Capital Gain -96.66% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.66% 3% F 2% F
Trailing 5 Years  
Capital Gain -100.00% N/A F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -100.00% N/A F N/A F
Average Annual (5 Year Horizon)  
Capital Gain -37.79% 7% C- 3% F
Dividend Return -37.79% 7% C- 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.30% 67% D+ 40% F
Risk Adjusted Return -79.90% 11% F 7% C-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector